Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of telmisartan + levoamlodipine tablets in patients with mild to moderate essential hypertension inadequately controlled after 4 weeks of telmisartan monotherapy
CTR20263916Phase 3Active
- Sponsor
- Jiangxi Shimei Pharmaceutical
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of telmisartan, Levamlodipine in essential hypertension, sponsored by Jiangxi Shimei Pharmaceutical. Started Nov 2026; status: active.
02
Drugs
telmisartanLevamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20263916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263916.